Red Flags Detected

  • Material Weakness (worsened) — Material weaknesses in internal controls remain unresolved for at least one year with no disclosed remediation efforts.
NYSE: APUS Apimeds Pharmaceuticals US, Inc. 10-Q

APUS posts $35M Q1 loss on crypto writedowns; new digital-asset segment now co-equal to pharma

Filed May 26, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 20, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade APUS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 27, 2026 2:56 PM